Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Biogen Idec
Woman and Man Max 99 years
Biogen Idec Research Limited
Update Il y a 4 ans
A Study of Multiple Doses of ISIS ISIS 396443 Delivered to Infants with Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy Uno studio di dosi multiple di ISIS 396443 somministrato a neonati con atrofia muscolare spinale in fase presintomatica geneticamente diagnosticata
The primary objective of the study is to examine the efficacy of multiple doses of ISIS 396443 administered intrathecally in preventing or delaying the need for respiratory intervention or death in in...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Biogen Idec Limited
Update Il y a 4 ans
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Part 1: The primary objective of the study is to investigate whether treatment with natalizumab slows the accumulation of disability not related to relapses in subjects with SPMS. Part 2: The pri...
Country
None
organs
None
Specialty
None
unknown
More information
Man Max 99 years
Biogen Idec Research Ltd
Update Il y a 4 ans
A clinical study involving people with severe haemophilia A to look at how safe an experimental replacement factor VIII protein (known as rFVIIIFc) is to take and how well it works to prevent and stop bleeds. Ensayo clínico con sujetos con Hemofilia A Severa para determinar cómo de seguro es tomar una proteína experimental que reemplaza al factor VIII (conocido como rFVIIIFc) y cómo de efectivo es en la prevención y la interrupción de los sangrados
The primary objective of the study is to evaluate the long-term safety of rFVIIIFc in subjects with hemophilia A. El objetivo principal del estudio es evaluar la seguridad a largo plazo de rFVII...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Biogen Idec Research Limited
Update Il y a 4 ans
A Study that evaluates effectiveness of Tecfidera® (Dimethyl Fumarate) in Multiple Sclerosis Patients in a Real World Setting
The primary objective of the study is to estimate the annualized relapse rate (ARR) in subjects with RRMS who are treated with DMF over a 12-month period.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Biogen Idec GmbH
Update Il y a 4 ans
A multicenter, randomized, rater-blind study to compare the efficacy and safety of natalizumab (300 mg IV every four weeks) with Interferon beta-1a (44 mcg SC three times a week) in subjects with relapsing multiple sclerosis previously treated with Interferon beta-1a (22 or 44 mcg SC three times a week)
The primary objective of this study is to compare the effect of natalizumab with IFN beta-1a on the annualized rate of clinical relapses at 1 year.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Biogen Idec Limited
Update Il y a 4 ans
A Study to Evaluate the Effect of Different Doses of TYSABRI on Safety and Efficacy in Relapsing Multiple Sclerosis
To explore the effects of multiple regimens of natalizumab on disease activity and safety in subjects with relapsing remitting MS.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Biogen Idec A/S
Update Il y a 4 ans
A Multi-centre, Double Blind, Randomised, Placebo Controlled, Parallel Group Study Investigating Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis
• The time to first documented relapse.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Biogen Idec Research Limited
Update Il y a 4 ans
A study to evaluate the effect of aspirin on flushing in patients with RRMS treated with Tecfidera
The primary objective of the study is to evaluate whether 150 mg enteric-coated ASA taken BID with DMF administration or 75 mg enteric-coated ASA taken once daily in the morning (QAM) with DMF adminis...
Country
None
organs
None
Specialty
None
Closed trial
More information
Man Max 99 years
Biogen Idec Hemophilia Inc
Update Il y a 4 ans
A clinical study involving people with severe haemophilia B to look at how safe an experimental replacement factor IX protein (known as rFIXFc) is to take and how well it works to prevent and stop bleeds
The primary objectives of the study are: • To evaluate the safety and tolerability of rFIXFc • To evaluate the efficacy of rFIXFc in all treatment arms: • To evaluate the effectiveness of prophylax...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Biogen Idec Research Limited
Update Il y a 4 ans
Efficacy and Safety of BIIB074 in Participants with Trigeminal Neuralgia
The primary objective of the study is to evaluate the efficacy of BIIB074 in treating pain experienced by subjects with TN. The primary objective of the LTE phase of the study is to evaluate the lon...
Country
None
organs
None
Specialty
None
unknown
More information
Previous
1
2
3
4
5
6
7
8
9
Next